We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Complete Blood Count Parameters Associated With Pancreatic Beta-Cell Function

By LabMedica International staff writers
Posted on 19 May 2022
Print article
Image: The Sysmex XE-2100D automated hematology analyzer (Photo courtesy of Bimedis)
Image: The Sysmex XE-2100D automated hematology analyzer (Photo courtesy of Bimedis)

The pathophysiology of type 2 diabetes mellitus (T2DM) involves insulin resistance (IR) and progressive deterioration of beta-cell function (BCF). Estimation of IR and BCF is essential for screening subjects at a high risk of T2DM and making treatment plans in clinical practice.

Along with other routine tests, the complete blood count (CBC) is widely used by physicians in health checkups to determine the status of patients and healthy people. Advances in technology make it possible for automatic cell counters to measure hematologic parameters related to variations in the shape and size of cells in addition to quantitative blood cell measurements, which contribute to the diagnosis and monitoring of many diseases.

Medical Laboratorians at the Korea Association of Health Promotion (Seoul, Korea) analyzed data from health examinees that underwent health checkups at 16 health-promotion centers in 13 Korean cities during 2021. The subjects comprised 1,470 patients with normoglycemia, 1,124 with prediabetes, and 396 with diabetes.

CBC parameters including hemoglobin level, RBC indices, and white blood cell (WBC), and platelet counts were measured using the Sysmex XE-2100D analyzer (Sysmex Corporation, Kobe, Japan). Pancreatic beta-cell function (BCF) and insulin resistance (IR) were assessed using the homeostasis model assessment (HOMA)-β and HOMA-IR, respectively.

Biochemical measurements, including those of fasting serum glucose, triglycerides, high-density lipoprotein cholesterol, and creatinine were made using the Hitachi 7600 analyzer (Hitachi, Tokyo, Japan). HbA1c levels were measured using ion-exchange high-performance liquid chromatography using the HLC-723 G8 analyzer (Tosoh, Tokyo, Japan). Serum insulin was measured using an electrochemiluminescence immunoassay with the Cobas e801 (Roche Diagnostics, Mannheim, Germany).

The investigators reported that while HOMA-IR gradually increased according to red blood cell count quartiles (1.22, 1.40, 1.47, and 1.91, in the first, second, third, and fourth quartiles, respectively), there was no correlation after adjusting for waist circumference (WC) and HbA1c. The red blood cell distribution width (RDW) was associated with HOMA-β, but not with HOMA-IR. White blood cells (WBCs) were associated with HOMA-IR and HOMA-β, which was stronger in HOMA-β after adjusting for WC and HbA1c. The platelet count was correlated with HOMA-IR and HOMA-β, which only remained in HOMA-β, after adjusting for WC and HbA1c.

The authors concluded that RDW, WBC, and platelet counts were independently associated with HOMA-β in prediabetes and T2DM. This suggests that these CBC parameters could represent BCF in prediabetes and T2DM. Due to its cost-effectiveness and easy accessibility, these CBC parameters could be screened periodically in prediabetes and T2DM, along with HbA1c, to keep both physicians and patients aware of the BCF of these diseases. The study was published on May 13, 2022 in the Journal of Clinical Laboratory Analysis.

Related Links:

Korea Association of Health Promotion 
Sysmex Corporation 
Hitachi 
Tosoh 
Roche Diagnostics 

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
Nutating Mixer
Enduro MiniMix

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.